What is your preferred adjuvant therapy for a patient with triple negative breast cancer and has a BRCA germline mutation who had minimal to no response to neoadjuvant chemotherapy?
Young patient, germline BRCA carrier with cT1cN0 to ypT2N0 disease after docetaxel/ cyclophosphamide x 4.
Community PollStarted
What systemic adjuvant therapy would you recommend for a BRCA carrier with significant residual disease after neoadjuvant TCx4?
39 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · H Lee Moffitt Cancer Center, University of South Florida
Answered on
The vast majority of OlympiA patients had both anthracycline and taxane therapy. Very few had less than 6 cycles of chemo or only one of the two agents. For this case, I would try to do 4 cycles of dose dense anthracycline treatments then adjuvant olaparib for 1 year.
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Mayo Clinic Rochester
Answered on
This is a challenging situation. Some variation of this scenario comes up pretty routinely: e.g. a patient who would have qualified for more therapy post-operatively than given neoadjuvantly with substantial residual disease. Unfortunately, many of the adjuvant studies (CREATE-X, OlympiA) don't refl...
Join for free or sign in to see the full answer